Liu M, Gu W, Chen L, Li Y, et al. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial. Diabetes Obes Metab 2024 Jun 22. doi: 10.1111/dom.15724.
PMID: 38922731